Aurobindo, Natco and Glenmark are among 8-9 global pharmaceutical companies that received FDA nod to launch Rizatriptan Benzoate orally disintegrating tablets (ODT), generic equivalents of Merck & Co Inc's Maxalt-MLT for use in adults and paediatric patients of 6-17 years.
The annual sales of the product during the year ended April 2013 amounted to $271 million, or Rs 1,616 crore, as per IMS data.
The annual sales of the product during the year ended April 2013 amounted to $271 million, or Rs 1,616 crore, as per IMS data.